Lymphocyte-to-C-reactive protein ratio is a potential new prognostic biomarker for patients with lung cancer
Lymphocyte-to-C-reactive protein ratio is a potential new prognostic biomarker for patients with lung cancer
复制标题
DOI：
10.2217/bmm-2019-0452
复制
发表时间：
2020-06-01
影响因子：
2.2
通讯作者：
Wang, Hai-Yun
中科院分区：
文献类型：
--
作者：
He, Yuan;Gong, Rui;Wang, Hai-Yun
目的：比较和评价不同炎症因子预处理组合对肺癌（LC）患者预后的价值。材料与方法：本研究纳入了1005例LC患者，并将其分为发现队列和验证队列。结果如下：在LC患者中，与其他参数相比，淋巴细胞-C-反应蛋白水平（LCR）与一线无进展生存期（PFS）和总生存期（OS）的相关性最高（p < 0.05），但与无病生存期无关（p > 0.05）。术前LCR降低是一线PFS和OS的独立预后因素（p < 0.05），但不是患者无病生存期的独立预后因素（p > 0.05）。结论：治疗前LCR是LC患者一线PFS和OS的有希望的生物标志物。
Aim: To compare and evaluate the prognostic value of various pretreatment combinations of inflammatory factors in patients with lung cancer (LC). Materials & methods: This study enrolled 1005 patients with LC and categorized into a discovery cohort and a validation cohort. Results: A combination of Lymphocyte-to-C-reactive protein levels (LCR) demonstrated the highest correlation with poor first-line progression-free survival (PFS) and overall survival (OS) (p < 0.05), but not disease-free survival (p > 0.05) compared with other parameters in LC patients. Decreased preoperative LCR was an independent prognostic factor for first-line PFS and OS (p < 0.05), but not disease-free survival (p > 0.05) in patients. Conclusion: Pretreatment LCR is a promising biomarker for first-line PFS and OS in patients with LC.